The antimalarial drug amodiaquine stabilizes p53 through ribosome biogenesis stress, independently of its autophagy-inhibitory activity

Pharmacological inhibition of ribosome biogenesis is a promising avenue for cancer therapy. Herein, we report a novel activity of the FDA-approved antimalarial drug amodiaquine which inhibits rRNA transcription, a rate-limiting step for ribosome biogenesis, in a dose-dependent manner. Amodiaquine tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Espinoza, Jaime A., Zisi, Asimina, Kanellis, Dimitris C., Carreras-Puigvert, Jordi, Henriksson, Martin, Hühn, Daniela, Watanabe, Kenji, Helleday, Thomas, Lindström, Mikael S., Bartek, Jiri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7205879/
https://www.ncbi.nlm.nih.gov/pubmed/31285544
http://dx.doi.org/10.1038/s41418-019-0387-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7205879/
https://www.ncbi.nlm.nih.gov/pubmed/31285544
http://dx.doi.org/10.1038/s41418-019-0387-5

Ejemplares similares